Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more
Biotechnology Assets S.A. (BST) - Net Assets
Latest net assets as of June 2025: €6.45 Million EUR
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has net assets worth €6.45 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.46 Million) and total liabilities (€7.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.45 Million |
| % of Total Assets | 47.95% |
| Annual Growth Rate | 8.21% |
| 5-Year Change | 71.98% |
| 10-Year Change | -12.69% |
| Growth Volatility | 54.79 |
Biotechnology Assets S.A. - Net Assets Trend (2010–2024)
This chart illustrates how Biotechnology Assets S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotechnology Assets S.A. (2010–2024)
The table below shows the annual net assets of Biotechnology Assets S.A. from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €6.61 Million | +1.19% |
| 2023-12-31 | €6.53 Million | +68.62% |
| 2022-12-31 | €3.87 Million | -10.73% |
| 2021-12-31 | €4.34 Million | +12.90% |
| 2020-12-31 | €3.84 Million | -49.16% |
| 2019-12-31 | €7.56 Million | -64.33% |
| 2018-12-31 | €21.19 Million | +164.03% |
| 2017-12-31 | €8.03 Million | +0.90% |
| 2016-12-31 | €7.96 Million | +5.09% |
| 2015-12-31 | €7.57 Million | -1.38% |
| 2014-12-31 | €7.68 Million | +80.95% |
| 2013-12-31 | €4.24 Million | +48.55% |
| 2012-12-31 | €2.86 Million | +9.77% |
| 2011-12-31 | €2.60 Million | +18.76% |
| 2010-12-31 | €2.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotechnology Assets S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4359.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €3.30 Million | 49.96% |
| Other Components | €26.88 Million | 406.48% |
| Total Equity | €6.61 Million | 100.00% |
Biotechnology Assets S.A. Competitors by Market Cap
The table below lists competitors of Biotechnology Assets S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Manaksia Limited
NSE:MANAKSIA
|
$8.44 Million |
|
Sino Logistics Corporation Public Company Limited
BK:SINO
|
$8.44 Million |
|
Knight Club Capital Asset Management PCL
BK:KCC
|
$8.44 Million |
|
ADM Hamburg Aktiengesellschaft
F:OEL
|
$8.45 Million |
|
Dignitana AB (publ.)
PINK:DIZTF
|
$8.43 Million |
|
HSS HIRE GROUP LS -01
F:HG3
|
$8.43 Million |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
$8.43 Million |
|
PSS EXOL SA D ZY 1
F:9B2
|
$8.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotechnology Assets S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,683,325 to 6,611,840, a change of -71,485 (-1.1%).
- Net loss of 2,917,307 reduced equity.
- Share repurchases of 120,525 reduced equity.
- Other comprehensive income decreased equity by 1,178,384.
- Other factors increased equity by 4,144,731.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.92 Million | -44.12% |
| Share Repurchases | €120.53K | -1.82% |
| Other Comprehensive Income | €-1.18 Million | -17.82% |
| Other Changes | €4.14 Million | +62.69% |
| Total Change | €- | -1.07% |
Book Value vs Market Value Analysis
This analysis compares Biotechnology Assets S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.43x to 2.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €0.52 | €0.22 | x |
| 2011-12-31 | €0.62 | €0.22 | x |
| 2012-12-31 | €0.68 | €0.22 | x |
| 2013-12-31 | €1.02 | €0.22 | x |
| 2014-12-31 | €1.73 | €0.22 | x |
| 2015-12-31 | €1.65 | €0.22 | x |
| 2016-12-31 | €1.59 | €0.22 | x |
| 2017-12-31 | €1.61 | €0.22 | x |
| 2018-12-31 | €0.54 | €0.22 | x |
| 2019-12-31 | €0.20 | €0.22 | x |
| 2020-12-31 | €0.10 | €0.22 | x |
| 2021-12-31 | €0.10 | €0.22 | x |
| 2022-12-31 | €0.07 | €0.22 | x |
| 2023-12-31 | €0.12 | €0.22 | x |
| 2024-12-31 | €0.10 | €0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotechnology Assets S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -116.02%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 2.24x
- Recent ROE (-44.12%) is below the historical average (-35.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 25.26% | 401.07% | 0.03x | 2.30x | €334.28K |
| 2011 | 11.84% | 106.57% | 0.04x | 2.80x | €47.97K |
| 2012 | -11.98% | -77.19% | 0.06x | 2.67x | €-627.67K |
| 2013 | 11.15% | 54.35% | 0.09x | 2.18x | €48.83K |
| 2014 | 15.55% | 63.46% | 0.13x | 1.91x | €425.77K |
| 2015 | -2.54% | -18.34% | 0.07x | 1.95x | €-949.61K |
| 2016 | -14.11% | -86.55% | 0.08x | 1.98x | €-1.94 Million |
| 2017 | -0.90% | -3.07% | 0.14x | 2.16x | €-889.20K |
| 2018 | -78.77% | -71.60% | 0.29x | 3.74x | €-18.81 Million |
| 2019 | -130.78% | -24.10% | 0.45x | 12.02x | €-10.85 Million |
| 2020 | -215.54% | -340.91% | 0.12x | 5.06x | €-9.01 Million |
| 2021 | -67.10% | -97.65% | 0.16x | 4.43x | €-3.46 Million |
| 2022 | -48.28% | -74.35% | 0.14x | 4.59x | €-2.35 Million |
| 2023 | 23.55% | 40.27% | 0.24x | 2.48x | €905.44K |
| 2024 | -44.12% | -116.02% | 0.17x | 2.24x | €-3.58 Million |
Industry Comparison
This section compares Biotechnology Assets S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $23,297,903
- Average return on equity (ROE) among peers: 1.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotechnology Assets S.A. (BST) | €6.45 Million | 25.26% | 1.09x | $8.44 Million |
| Atrys Health SL (ATRY) | $23.30 Million | 1.25% | 0.73x | $124.28 Million |